期刊
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS
卷 12, 期 5, 页码 618-627出版社
SPRINGER
DOI: 10.1007/s11910-012-0294-3
关键词
Multiple sclerosis (MS); Cognitive impairment; Assessment; Neuropsychological tests; Processing speed; Memory; Disease-modifying therapies (DMTs); Interferon; Amphetamine; Cholinesterase inhibitors; Exercise; Yoga; Symptomatic treatment; Cognitive rehabilitation; Complementary and alternative treatments; Functional connectivity; MRI; fMRI; Lesion load; Theory of mind; Imaging correlates of MS; Domains of impairment; Prevalence; Incidence; Cortical pathology
资金
- NCCIH NIH HHS [K23 AT004433] Funding Source: Medline
Cognitive impairment (CI) is a serious complication of multiple sclerosis (MS), and the domains affected are well established, but new affected domains such as theory of mind are still being identified. The evidence that disease-modifying therapies (DMTs) improve and prevent the development of CI in MS is not solid. Recent studies on the prevalence of CI in MS among people treated with DMT, although not as solid as studies completed prior to DMT introduction, suggest that CI remains a problem even among people on DMTs and that CI occurs frequently even at the very earliest stages of MS. Functional MRI studies and studies using diffusion tractography show that the impact of lesions on cognition depends on the particular cortical networks affected and their plasticity. Cognitive rehabilitation and L-amphetamine appear promising symptomatic treatments for CI in MS, while, cholinesterase inhibitors and memantine have failed, and data on Ginkgo and exercise are limited. We need more work to understand better CI in MS and develop treatments for this serious complication of MS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据